Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation. However, adverse events associated with pralsetinib and selpercatin...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Kaidiriye Setiwalidi, Yimeng Li, Yuyan Ma, Zhanpeng Hao, Yujia Zhao, Yuxin Zhang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao, Xiao Fu
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-11-01
Serija:	Frontiers in Oncology
Teme:	NSCLC RET pralsetinib selpercatinib invasive aspergillosis
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1431908/full
Oznake:	Označite Brez oznak, prvi označite!